Literature DB >> 28418276

Thrombin-antithrombin III complex tests.

Sang Yang Lee1, Takahiro Niikura1, Takashi Iwakura1, Yoshitada Sakai2, Ryosuke Kuroda1, Masahiro Kurosaka1.   

Abstract

PURPOSE: Patients with fractures of the pelvis and/or lower extremities are at a high risk of developing postoperative venous thromboembolism (VTE). The purpose of this study was to determine whether the thrombin-antithrombin III complex (TAT) tests could be used for postoperative screening of VTE in patients with lower limb or pelvic fractures.
METHODS: We enrolled 133 patients who underwent surgical treatment for fracture of the pelvis or lower extremities. TAT and D-dimer levels were compared in patients with and without VTE. Receiver operating characteristic (ROC) curve analysis was done and the appropriate TAT and D-dimer cutoff levels were determined for VTE screening.
RESULTS: VTE was diagnosed in 41 patients (30.8%). Patients with VTE had significantly higher levels of TAT and D-dimer on postoperative days 1, 3, and 7 than those without VTE, respectively. ROC curve analysis suggested that TAT test at postoperative day 7 had the highest accuracy for predicting postoperative VTE. With the optimal cutoff TAT level of 3.0 ng/mL, sensitivity and specificity were 93.3% and 70.1%, respectively. With the optimal cutoff D-dimer level of 7.4 µg/mL, sensitivity and specificity were 93.3% and 57.0%, respectively.
CONCLUSION: TAT levels measured at postoperative day 7 could be the most useful parameter for screening postoperative VTE. TAT can be used as a screening tool for screening postoperative VTE in patients with lower limb and pelvic fractures.

Entities:  

Keywords:  deep venous thrombosis (DVT); fracture; pulmonary thromboembolism (PTE); thrombin–antithrombin III complex (TAT); venous thromboembolism (VTE)

Mesh:

Substances:

Year:  2017        PMID: 28418276     DOI: 10.1177/0170840616684501

Source DB:  PubMed          Journal:  J Orthop Surg (Hong Kong)        ISSN: 1022-5536            Impact factor:   1.118


  7 in total

1.  Cardiovascular resistance to thrombosis in 13-lined ground squirrels.

Authors:  Alison Bonis; Leah Anderson; Gaëlle Talhouarne; Emily Schueller; Jenna Unke; Catherine Krus; Jordan Stokka; Anna Koepke; Brittany Lehrer; Anthony Schuh; Jeremiah J Andersen; Scott Cooper
Journal:  J Comp Physiol B       Date:  2018-10-13       Impact factor: 2.200

2.  Binding domain peptide ameliorates alveolar hypercoagulation and fibrinolytic inhibition in mice with lipopolysaccharide-induced acute respiratory distress syndrome Via NF-κB signaling pathway.

Authors:  Yahui Wang; Yanqi Wu; Bo Liu; Huilin Yang; Hong Qian; Yumei Cheng; Xiang Li; Guixia Yang; Xinghao Zheng; Feng Shen
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  NLR value and IL-18 level and their clinical significance in patients with deep vein thrombosis after receiving the surgery for spinal degeneration.

Authors:  Yukun Zhang; Mingyu Cao; Jun Ren
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 4.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

5.  Clinical Impact of Coagulation and Fibrinolysis Markers for Predicting Postoperative Venous Thromboembolism in Total Joint Arthroplasty Patients.

Authors:  Yuying Cheng; Jian Liu; Yu Su; Huiru Zhao; Yujing Zhao; Meng Wen; Shan Lu; Wenjie Zhang; Jun Wu
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

6.  Clinical Features and Prognostic Factors of Acute Ischemic Stroke Related to Malignant Gastrointestinal Tumor.

Authors:  Yating Liu; Xin Li; Feixue Song; Xin Yan; Zhijian Han; Futian Tang; Yumin Li
Journal:  Front Neurol       Date:  2021-11-25       Impact factor: 4.003

7.  Prevalence and Characteristics of Hepatic Hemangioma Associated with Coagulopathy and Its Predictive Risk Factors.

Authors:  Shigeo Maruyama; Tomomitsu Matono; Masahiko Koda
Journal:  J Clin Med       Date:  2022-07-26       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.